Multiplex Assay Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay)

TRAP; TrATPase; Tartrate Resistant Acid Phosphatase; Type 5 acid phosphatase

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 97-105 101
EDTA plasma(n=5) 94-103 97
heparin plasma(n=5) 82-94 89

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 97-105% 85-94% 79-93% 98-105%
EDTA plasma(n=5) 79-96% 80-101% 78-102% 87-101%
heparin plasma(n=5) 94-101% 78-102% 84-105% 89-98%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:ACP5) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Archives of Oral Biology Oxytocin promotes bone formation during the alveolar healing process in old acyclic female rats ScienceDirect: S0003996912001021
Life Sciences Exendin-4 Increases Bone Mineral Density in Type 2 Diabetic OLETF Rats Potentially Through the Down-Regulation of SOST/Sclerostin in Osteocytes PubMed: 23357248
International Journal of Cardiology Valvular osteoclasts in calcification and aortic valve stenosis severity. Pubmed: 23452891
Evidence-Based Complementary and Alternative Medicine Antiosteoporosis Activity of New Oriental Medicine Preparation (Kyungokgo Mixed with Water Extract of Hovenia dulcis) on the Ovariectomized Mice Pubmed:25737735
Advances in Medical Sciences The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats PubMed: 26569440
Bone The effects of strength training and raloxifene on bone health in aging ovariectomized rats Pubmed:26812611
Journal of Clinical Medicine Research In Vitro and In Vivo Effects of Gracilaria verrucosa Extracts on Osteoclast Differentiation. pubmed:28335442
Biomedicine & Pharmacotherapy Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats S0753332216322752
Clinical Trials in Degenerative Diseases Correlating oxidative stress-related factors with bone metabolic markers in older adult male patients exhibiting degenerative osteoporosis in the high-altitude hypoxic area of China: study protocol for a non-randomized controlled trial issn:2542-3975
Scientific Reports Evidence for excessive osteoclast activation in SIRT6 null mice Pubmed:30030453
International Journal of Molecular Sciences  Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo Pubmed:29562730
Experimental Gerontology The decline of whole-body glucose metabolism in ovariectomized rats Pubmed: 30292771
Bone Research NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblasts Pubmed: 30455992
Cell Death & Disease QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism Pubmed: 32382069
Effect of Corticopuncture (CP), Photobiomodulation (PBM) and the Combined Method on the Rate of Tooth Movement and Root Resorption: A Molecular, Histological …
Evid Based Complement Alternat Med Gujiansan Ameliorates Avascular Necrosis of the Femoral Head by Regulating Autophagy via the HIF-1α/BNIP3 Pathway 34512780
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPA902Hu01 Recombinant Acid Phosphatase 5, Tartrate Resistant (ACP5) Positive Control; Immunogen; SDS-PAGE; WB.
PAA902Hu01 Polyclonal Antibody to Acid Phosphatase 5, Tartrate Resistant (ACP5) WB; IHC; ICC; IP.
MAA902Hu22 Monoclonal Antibody to Acid Phosphatase 5, Tartrate Resistant (ACP5) WB; IHC; ICC; IP.
SEA902Hu ELISA Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA902Hu Multiplex Assay Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.